Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Current Leases (2019 - 2025)

Keros Therapeutics filings provide 7 years of Current Leases readings, the most recent being $2.4 million for Q4 2025.

  • On a quarterly basis, Current Leases rose 21.74% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 21.74% increase, with the full-year FY2025 number at $2.4 million, up 21.74% from a year prior.
  • Current Leases hit $2.4 million in Q4 2025 for Keros Therapeutics, up from $2.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.4 million in Q4 2025 to a low of $436000.0 in Q1 2021.
  • Median Current Leases over the past 5 years was $944500.0 (2022), compared with a mean of $1.2 million.
  • Biggest five-year swings in Current Leases: crashed 47.22% in 2022 and later surged 203.93% in 2024.
  • Keros Therapeutics' Current Leases stood at $862000.0 in 2021, then crashed by 47.22% to $455000.0 in 2022, then soared by 120.88% to $1.0 million in 2023, then surged by 96.82% to $2.0 million in 2024, then rose by 21.74% to $2.4 million in 2025.
  • The last three reported values for Current Leases were $2.4 million (Q4 2025), $2.3 million (Q3 2025), and $2.2 million (Q2 2025) per Business Quant data.